The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the advanced gastric cancer expansion cohort.
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Satoru Iwasa
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Motohiro Hirao
No Relationships to Disclose
 
Takashi Oshima
Research Funding - Chugai Pharma; Daiichi Sankyo; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kazuaki Harada
Honoraria - Bayer; Chugai Pharma; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Yasuyoshi Sato
Honoraria - Bristol-Myers Squibb; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Akihito Kawazoe
Honoraria - Bristol-Myers Squibb; Ono Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Kan Yonemori
Honoraria - AstraZeneca; Eisai; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis; Ono Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Kazuhiro Nishikawa
Honoraria - Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Lilly; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Nozomu Machida
Consulting or Advisory Role - AstraZeneca; MSD
Speakers' Bureau - Bristol-Myers Squibb; Daiichi Sankyo; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - AstraZeneca; MSD
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Takuya Suzuki
Employment - Eisai
 
Shiori Okumura
Employment - Eisai
 
Reiko Nagai
Employment - Eisai
Stock and Other Ownership Interests - Eisai
 
Takao Takase
Employment - Eisai
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)